Vantictumab, formerly known as OMP18R5, represents an novel monoclonal antibody designed to specifically inhibit osteopontin molecule 18R5. Such treatment is actively evaluated by Amgen in anticipated treatments in https://www.targetmol.com/compound/vantictumab